Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Jean Marie Arduino"'
Autor:
Chizoba Nwankwo, Kathryn Eilene Lasch, Jean Marie Arduino, Jacqueline Mary Lustrino, Jan Sperl, Xinyi Ng, Shelby Corman, Heather L. Platt, Jingjun Qiu, S. Patel
Publikováno v:
Patient preference and adherence
Xinyi Ng,1 Chizoba Nwankwo,2 Jean Marie Arduino,2 Shelby Corman,1 Kathryn Eilene Lasch,1 Jacqueline Mary Lustrino,1 Sushma Patel,2 Heather Loryn Platt,2 Jingjun Qiu,2 Jan Sperl3 1Pharmerit International, LP, Bethesda, MD, USA; 2Merck & Co. Inc., Keni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc017adc28efcd907764336a3da37a22
http://europepmc.org/articles/PMC6294167
http://europepmc.org/articles/PMC6294167
Autor:
Abdul-Badi Abou-Samra, Adeel A. Butt, Amy Puenpatom, Ritesh N. Kumar, Yanjie Ren, Jean-Marie Arduino
Publikováno v:
Liver International. 38:1411-1417
Background Newer direct acting antiviral agents against HCV (DAAs) are safe and efficacious in persons with chronic kidney disease (CKD). Whether approval of newer DAAs has resulted in more persons with CKD initiating HCV treatment remains unknown. M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de22e8244870d394da025f5a043a49bd
https://doi.org/10.1111/liv.13672
https://doi.org/10.1111/liv.13672
Autor:
Craig A. Solid, Senaka Peter, Tanya Natwick, Haifeng Guo, Allan J. Collins, Jean Marie Arduino
Publikováno v:
Nephron. 136:54-61
Background/Aims: Few studies explore the magnitude of the disease burden and health care utilization imposed by renal disease among patients with hepatitis C virus (HCV). We aimed to describe the characteristics, outcomes, and health care utilization
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a28c97010eab8898eabd0d728f433898
https://doi.org/10.1159/000454684
https://doi.org/10.1159/000454684
Autor:
Abdul-Badi Abou-Samra, Y. Ren, Jean Marie Arduino, Ritesh N. Kumar, Adeel A. Butt, Amy Puenpatom
Publikováno v:
Alimentary pharmacologytherapeutics. 48(1)
Background Chronic kidney disease (CKD) was a relative contraindication to hepatitis C virus (HCV) treatment in the interferon/ribavirin era. Aim To determine the efficacy, tolerability and safety of sofosbuvir/ledipasvir (SOF/LDV) and paritaprevir/r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::355bd2e7cf5d6c2d6411a9fc96ee81c4
https://pubmed.ncbi.nlm.nih.gov/29998505
https://pubmed.ncbi.nlm.nih.gov/29998505
Autor:
Michael A. Horberg, Stephen F. Derose, Jean Marie Arduino, Rong Wei, Kevin B Rubenstein, Sara Y. Tartof, Lei Qian, Jin-Wen Hsu, Carla V. Rodriguez, Haihong Hu
Publikováno v:
Clinical journal of the American Society of Nephrology : CJASN. 13(10)
BACKGROUND AND OBJECTIVES: Studies evaluating the role of hepatitis C viral (HCV) infection on the progression of CKD are few and conflicting. Therefore, we evaluated the association of untreated HCV on kidney function decline in patients with stage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::640bee2900d911695b99d49b38dc4bc8
https://pubmed.ncbi.nlm.nih.gov/30242027
https://pubmed.ncbi.nlm.nih.gov/30242027
Autor:
Stanislas Pol, David Roth, Janice Wahl, Wayne Greaves, Maria Carlota Londoño, Peggy Hwang, David R. Nelson, Marcelo Silva, Paul J. Martin, Bach-Yen Nguyen, Eliav Barr, Howard Paul Monsour, Jean Marie Arduino, Annette Bruchfeld, Michael N. Robertson
Publikováno v:
The lancet. Gastroenterologyhepatology. 2(8)
Summary Background In the C-SURFER study, therapy with the all-oral elbasvir plus grazoprevir regimen for 12 weeks in patients with chronic hepatitis C virus (HCV) infection and stage 4–5 chronic kidney disease resulted in a high rate of virologica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b8448f9de94d18267e2cc2cddbfd3af
https://pubmed.ncbi.nlm.nih.gov/28691680
https://pubmed.ncbi.nlm.nih.gov/28691680
Autor:
Jean Marie Arduino, Kathy Schulman, Girish Prajapati, Gregory Fusco, Jennifer S Fusco, Ricky Hsu
Publikováno v:
Open Forum Infectious Diseases
Background Raltegravir has been used to treat HIV infection for over a decade. In 2017, a 1200 mg, once-daily, formulation of raltegravir (RALQD) was approved. We sought to characterize the utilization and effectiveness of RALQD in ART-experienced, v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a54c38030341cb4bc2b5e76ebabee691
http://europepmc.org/articles/PMC6810617
http://europepmc.org/articles/PMC6810617
Autor:
Steven S. Smugar, Tessie McNeely, Nicholas A. Kartsonis, Dlawer A. A. Ala'Aldeen, Jean Marie Arduino, Barry N. Kreiswirth, Mark T. Esser, Annaliesa S. Anderson, Michael D. Raedler, Julie K. Zorman
Publikováno v:
Human Vaccines & Immunotherapeutics. 9:1857-1864
Staphylococcus aureus is a well-recognized, clinically important cause of nosocomial infections, and as such, a vaccine to prevent S. aureus infections would be an important achievement. A Phase IIB/III study of V710, a vaccine containing iron-regula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c85370f25112c08dfedd8da73ea53748
https://doi.org/10.4161/hv.25253
https://doi.org/10.4161/hv.25253
Autor:
Jean Marie Arduino, Jin-Wen Hsu, Carla V. Rodriguez, Sara Y. Tartof, Kevin B Rubenstein, Rong Wei, Haihong Hu, Michael A. Horberg, Stephen F. Derose
Publikováno v:
Open Forum Infectious Diseases. 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c20bcc82a8471d67d9bd4609cbdb220
https://doi.org/10.1093/ofid/ofw172.302
https://doi.org/10.1093/ofid/ofw172.302
Autor:
Kevin B Rubenstein, Michael A. Horberg, Jean Marie Arduino, Stephen F. Derose, Carla V. Rodriguez, Haihong Hu, Rong Wei, Jin-Wen Hsu, Sara Y. Tartof
Publikováno v:
Open Forum Infectious Diseases. 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbace1eb07eb84b25af392eac3ad7147
https://doi.org/10.1093/ofid/ofw172.298
https://doi.org/10.1093/ofid/ofw172.298